Avacta Group PLC Notice of AGM, Accounts and Directorate Change (5612Q)
December 01 2016 - 2:00AM
UK Regulatory
TIDMAVCT
RNS Number : 5612Q
Avacta Group PLC
01 December 2016
1 December 2016
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Notice of AGM, posting of accounts and Directorate change
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and research reagents, confirms that the Annual
Report and Accounts for the year ended 31 July 2016, the Notice of
the Annual General Meeting and a Form of Proxy were posted to
shareholders on 1 December 2016.
Craig Slater, the Group's Chief Operating Officer will not seek
re-election at the forthcoming Annual General Meeting to be held on
Friday 20 January 2017. Accordingly, he will cease to be a board
member from that date although will remain with the Company,
overseeing the Animal Health business.
Dr. Trevor Nicholls, Non-executive Chairman of Avacta Group,
commented:
"The Board would like to thank Craig for his significant
contribution to the Group since he joined the Board in 2013. Craig
will remain with the Group as Chief Operating Officer and continue
to oversee Avacta Animal Health."
The Annual General Meeting is to be held on Friday 20 January
2017 at 10.00am GMT at the offices of FTI Consulting, 200
Aldersgate, Aldersgate Street, London, EC1A 4HD.
A copy of the Annual Report & Accounts and Notice of Annual
General Meeting is available on the Company's website:
www.avacta.com.
ENDS
Notes to Editors
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0) 844
Alastair Smith, Chief Executive 414 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
finnCap Ltd Tel: +44 (0) 207
Geoff Nash / Giles Rolls - Nominated 220 0500
Adviser www.finncap.com
Tim Redfern / Alice Lane - Corporate
Broking
Tel: +44 (0) 203
WG Partners 705 9318
David Wilson Tel: +44 (0) 203
Nigel Barnes 705 9217
Claes Spang www.wgpartners.co.uk
FTI Consulting (Financial Media Tel: +44 (0) 203
and IR) 727 1000
Simon Conway / Natalie Garland-Collins avacta@fticonsulting.com
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $75bn despite
their shortcomings. Affimer technology has been designed to address
many of these negative performance issues, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of targets to enable diagnostics, research assays
and therapeutics.
Avacta has a pre-clinical therapeutic development programme with
an in-house focus on immuno-oncology and bleeding disorders as well
as partnered development programmes. Avacta is commercialising
non-therapeutic Affimer reagents through licensing to developers of
life sciences research tools and diagnostics.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCAKKDBDBDDODN
(END) Dow Jones Newswires
December 01, 2016 02:00 ET (07:00 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024